Drug Profile

ACT 901

Alternative Names: ACT-901; AFP-paclitaxel; Alpha-fetoprotein-paclitaxel conjugate; Third generation paclitaxel therapy

Latest Information Update: 11 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alpha Cancer Technologies
Class Antineoplastics; Diterpenes; Drug conjugates; Paclitaxels; Small molecules; Taxanes
Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

11 Mar 2025 ACT 901 is still in preclinical trials in Cancer in Canada (unspecified route) (Alpha Cancer Technologies, pipeline, March 2025)
28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in Canada
28 Jul 2020 ACT 901 is still in preclinical development in Cancer in Canada

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com